KDSR (Q06136) review notes

Gene: KDSR / FVT1 / SDR35C1, human. 332 aa, ER membrane, short-chain dehydrogenase/reductase (SDR) family.

Core biology (verified)

KDSR catalyses the second step of de novo sphingolipid biosynthesis: the NADPH-dependent
reduction of 3-ketodihydrosphingosine (3-ketosphinganine / 3-oxosphinganine, "3KDS") to
dihydrosphingosine (sphinganine). This follows the SPT-catalysed condensation of L-serine +
palmitoyl-CoA and precedes N-acylation by the ceramide synthases (CERS).
- EC 1.1.1.102; RHEA:22640; the physiological direction is reduction (right-to-left in the UniProt
Rhea reaction sphinganine + NADP(+) = 3-oxosphinganine + NADPH + H(+)).
- The only KDS reductase in mammals; silencing directly reduces cellular reductase activity
PMID:19141869.
- Human FVT-1 rescues TSC10-null yeast and purified recombinant hFVT-1 has NADPH-dependent KDS
reductase activity in vitro PMID:15328338.

Localization / topology (verified)

ER membrane, multi-pass; the large hydrophilic catalytic domain (with the active-site residues)
faces the cytosol [PMID:15328338; PMID:1317856]. UniProt: two C-terminal TM helices (271-291,
294-314), cytoplasmic catalytic domain 26-270. GO:0098554 (cytoplasmic side of ER membrane) is
therefore the most precise CC.

Disease (verified)

Cancer relevance

In some cancers KDSR clears the toxic intermediate 3KDS; KDSR loss causes 3KDS accumulation,
ER dysfunction and proteotoxic stress -> potential therapy target [PMID:36170811 (full text cached)].

Annotation-level notes / issues